Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 2, Open-label, 2-arm, Response Rate Study Of Talazoparib In Men With Dna Repair Defects And Metastatic Castration-resistant Prostate Cancer Who Previously Received Taxane-based Chemotherapy And Progressed On At Least 1 Novel Hormonal Agent (Enzalutamide And / or Abiraterone Acetate / Prednisone)

Status
Active
Cancer Type
Prostate Cancer
Unknown Primary
Trial Phase
Phase II
Eligibility
18 Years and older, Male
Study Type
Treatment
NCD ID
NCT03148795
Protocol IDs
MDV3800-06 (primary)
NCI-2017-01403
C3441006
2016-002036-32
Study Sponsor
Pfizer

Summary

The purpose of this international, phase 2, open-label, 2-arm, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and / or abiraterone acetate / prednisone).
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.